Immune to Cancer: The CRI Blog
-
ASCO20 Preview: Unite & Conquer – Accelerating Progress Together
The ASCO20 Annual Meeting kicks off virtually on Friday, May 31—and advances in immunotherapy will be a…
-
AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights
The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…
-
AACR20 Day 1 Highlights: Breast Cancer, Lung Cancer, and the Microbiome
The first day of the 2020 AACR Annual Meeting shared latest data from immunotherapy clinical trials in…
-
PORTER Immunotherapy Clinical Trial for Prostate Cancer Unveiled at SITC2019
Details of a promising new CRI co-funded clinical trial for metastatic prostate cancer unveiled at the 2019…
-
CICON19 Day 4 Update: Metabolic Crosstalk and the Microbiome
Day 4 of CICON19 highlighted breakthroughs in our understanding of the metabolic crosstalk within the tumor microenvironment as…
-
CICON19 Day 3 Update: Vaccines and Tumor Antigens, Technology and Informatics, and the Tumor Microenvironment
Day 3 of CICON19 explored current strategies to identify tumor neoantigens and develop vaccines as well as advances…
-
CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies
Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…
-
CICON19 Preview: Translating Science into Survival
Topics at the upcoming CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON19) in Paris include prevention, the tumor microenvironment,…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…